Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
7.49
+0.33 (4.61%)
Apr 30, 2026, 2:54 PM EDT - Market open
Unicycive Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Unicycive Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $25.67, which forecasts a 242.72% increase in the stock price over the next year. The lowest target is $15 and the highest is $40.
Price Target: $25.67 (+242.72%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Unicycive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Buy Maintains $21 → $15 | Buy | Maintains | $21 → $15 | +100.27% | Apr 6, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $46 → $40 | Strong Buy | Maintains | $46 → $40 | +434.05% | Apr 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $22 | Strong Buy | Maintains | $9 → $22 | +193.72% | Oct 29, 2025 |
| Benchmark | Benchmark | Buy Maintains $3 → $21 | Buy | Maintains | $3 → $21 | +180.37% | Sep 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $90 | Strong Buy | Initiates | $90 | +1,101.60% | May 27, 2025 |
Financial Forecast
Revenue This Year
70.35M
Revenue Next Year
480.39M
from 70.35M
Increased by 582.86%
EPS This Year
-1.35
from -1.67
EPS Next Year
15.03
from -1.35
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 241.2M | 1.2B | ||||||
| Avg | 70.4M | 480.4M | ||||||
| Low | 7.3M | 91.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,598.6% | ||||||
| Avg | - | 582.9% | ||||||
| Low | - | 29.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.95 | 30.60 | ||||||
| Avg | -1.35 | 15.03 | ||||||
| Low | -1.72 | 6.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.